SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $929 | -96.9% | 64 | -95.5% | 0.00% | – |
| Q2 2023 | $29,972 | +166411.1% | 1,432 | +68.1% | 0.00% | – |
| Q1 2023 | $18 | +1700.0% | 852 | +1928.6% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 42 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -97.4% | 42 | -98.1% | 0.00% | – |
| Q1 2022 | $38,000 | +8.6% | 2,160 | 0.0% | 0.00% | – |
| Q4 2021 | $35,000 | -23.9% | 2,160 | -10.0% | 0.00% | – |
| Q3 2021 | $46,000 | +12.2% | 2,400 | 0.0% | 0.00% | – |
| Q2 2021 | $41,000 | +272.7% | 2,400 | +380.0% | 0.00% | – |
| Q1 2021 | $11,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q4 2020 | $11,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |